Vivet Therapeutics, supported by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals

by Ysios Capital

Vivet’s second gene therapy product, VTX-803 for PFIC3, received US and European Orphan Drug Designation in May 2020.Vivet is supported by international life science investors including Novartis Ven...

Read more

Pfizer secures exclusive option to acquire gene therapy company vivet therapeutics

by Ysios Capital

Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partner...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

MiiN Cosmetics da entrada a Barlon Capit...

by Barlon Capital

MiiN Cosmetics, la marca de cosmética coreana de referencia en Europa...

Photos Stream